{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:55:19Z","timestamp":1790826919613,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.trim.2023.101857","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:15Z","timestamp":1684281615000},"page":"101857","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Increased CMV disease and \u201csevere\u201d BK viremia with belatacept vs. sirolimus three-drug maintenance immunosuppression"],"prefix":"10.1016","volume":"79","author":[{"given":"Gregory","family":"Petrossian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro Chiodo","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Addonizio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosy","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoru","family":"Koizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Plews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.trim.2023.101857_bb0005","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1111\/ajt.14721","article-title":"De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies","volume":"18","author":"Bray","year":"2018","journal-title":"Am. J. Transplant."},{"issue":"9","key":"10.1016\/j.trim.2023.101857_bb0010","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/ajt.12795","article-title":"A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients","volume":"14","author":"Lim","year":"2014","journal-title":"Am. J. Transplant."},{"issue":"2","key":"10.1016\/j.trim.2023.101857_bb0015","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/aor.13551","article-title":"Tacrolimus: 20 years of use in adult kidney transplantation. What we should know about its nephrotoxicity","volume":"44","author":"Bentata","year":"2020","journal-title":"Artif. Organs"},{"issue":"1","key":"10.1016\/j.trim.2023.101857_bb0020","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/j.ackd.2019.08.006","article-title":"The many faces of calcineurin inhibitor toxicity-what the FK?","volume":"27","author":"Farouk","year":"2020","journal-title":"Adv. Chronic Kidney Dis."},{"issue":"3","key":"10.1016\/j.trim.2023.101857_bb0025","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1600-6143.2004.00332.x","article-title":"Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era","volume":"4","author":"Meier-Kriesche","year":"2004","journal-title":"Am. J. Transplant."},{"issue":"1","key":"10.1016\/j.trim.2023.101857_bb0030","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40265-019-01226-6","article-title":"Costimulation blockade in kidney transplant recipients","volume":"80","author":"van der Zwan","year":"2020","journal-title":"Drugs."},{"issue":"3","key":"10.1016\/j.trim.2023.101857_bb0035","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-6143.2009.03005.x","article-title":"A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)","volume":"10","author":"Vincenti","year":"2010","journal-title":"Am. J. Transplant."},{"issue":"5","key":"10.1016\/j.trim.2023.101857_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8050594","article-title":"Epidemiology, risk factors, and outcomes of opportunistic infections after kidney allograft transplantation in the era of modern immunosuppression: a monocentric cohort study","volume":"8","author":"Attias","year":"2019","journal-title":"J. Clin. Med."},{"issue":"10","key":"10.1016\/j.trim.2023.101857_bb0045","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a015669","article-title":"Opportunistic infections--coming to the limits of immunosuppression?","volume":"3","author":"Fishman","year":"2013","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"14","key":"10.1016\/j.trim.2023.101857_bb0050","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.7150\/ijms.62621","article-title":"The incidence and effect of cytomegalovirus disease on mortality in transplant recipients and general population: real-world nationwide cohort data","volume":"18","author":"Han","year":"2021","journal-title":"Int. J. Med. Sci."},{"issue":"3","key":"10.1016\/j.trim.2023.101857_bb0055","doi-asserted-by":"crossref","first-page":"270","DOI":"10.12998\/wjcc.v7.i3.270","article-title":"Incidence, risk factors, and outcome of BK polyomavirus infection after kidney transplantation","volume":"7","author":"Favi","year":"2019","journal-title":"World J. Clin. Cases."},{"issue":"2","key":"10.1016\/j.trim.2023.101857_bb0060","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/ndt\/gfu023","article-title":"BK virus infection: an update on diagnosis and treatment","volume":"30","author":"Sawinski","year":"2015","journal-title":"Nephrol. Dial. Transplant."},{"issue":"3","key":"10.1016\/j.trim.2023.101857_bb0065","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/tid.12530","article-title":"In kidney transplant recipients with BK polyomavirus infection, early BK nephropathy, microvascular inflammation, and serum creatinine are risk factors for graft loss","volume":"18","author":"Mohamed","year":"2016","journal-title":"Transpl. Infect. Dis."},{"issue":"2","key":"10.1016\/j.trim.2023.101857_bb0070","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/ndt\/gfz255","article-title":"Opportunistic infections after conversion to belatacept in kidney transplantation","volume":"35","author":"Bertrand","year":"2020","journal-title":"Nephrol. Dial. Transplant."},{"issue":"22","key":"10.1016\/j.trim.2023.101857_bb0075","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.2146\/ajhp120770","article-title":"Risk of posttransplant lymphoproliferative disorder associated with use of belatacept","volume":"70","author":"Martin","year":"2013","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"4","key":"10.1016\/j.trim.2023.101857_bb0080","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1128\/CMR.00015-13","article-title":"Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantation","volume":"26","author":"Razonable","year":"2013","journal-title":"Clin. Microbiol. Rev."},{"issue":"1","key":"10.1016\/j.trim.2023.101857_bb0085","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/ajt.16132","article-title":"CMV high-risk status and posttransplant outcomes in kidney transplant recipients treated with belatacept","volume":"21","author":"Karadkhele","year":"2021","journal-title":"Am. J. Transplant."},{"issue":"1","key":"10.1016\/j.trim.2023.101857_bb0090","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1128\/CMR.00062-12","article-title":"The \u201csilent\u201d global burden of congenital cytomegalovirus","volume":"26","author":"Manicklal","year":"2013","journal-title":"Clin. Microbiol. Rev."},{"issue":"6","key":"10.1016\/j.trim.2023.101857_bb0095","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1399-3062.2010.00532.x","article-title":"Choice of induction regimens on the risk of cytomegalovirus infection in donor-positive and recipient-negative kidney transplant recipients","volume":"12","author":"Luan","year":"2010","journal-title":"Transpl. Infect. Dis."},{"issue":"6","key":"10.1016\/j.trim.2023.101857_bb0100","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1399-3062.2010.00533.x","article-title":"Cytomegalovirus risk factors in renal transplantation with modern immunosuppression","volume":"12","author":"Bataille","year":"2010","journal-title":"Transpl. Infect. Dis."},{"issue":"4","key":"10.1016\/j.trim.2023.101857_bb0105","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/01.TP.0000148239.00384.F0","article-title":"Clinical and immunologic aspects of cytomegalovirus infection in solid organ transplant recipients","volume":"79","author":"Rowshani","year":"2005","journal-title":"Transplantation."},{"issue":"1","key":"10.1016\/j.trim.2023.101857_bb0110","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1586\/14787210.5.1.105","article-title":"Antivirals for the treatment of polyomavirus BK replication","volume":"5","author":"Rinaldo","year":"2007","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"10.1016\/j.trim.2023.101857_bb0115","first-page":"47","article-title":"BK virus in transplant recipients: current perspectives","volume":"11","author":"Muhsin","year":"2019","journal-title":"Transp. Res. Risk Manag."},{"issue":"4","key":"10.1016\/j.trim.2023.101857_bb0120","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/CM9.0000000000000085","article-title":"Prognosis of BK polyomavirus nephropathy: 10-year analysis of 133 renal transplant recipients at a single center","volume":"132","author":"Chen","year":"2019","journal-title":"Chin. Med. J."},{"issue":"12","key":"10.1016\/j.trim.2023.101857_bb0125","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1097\/TP.0b013e3182708e56","article-title":"Is cytomegalovirus prophylaxis dispensable in patients receiving an mTOR inhibitor-based immunosuppression? A systematic review and meta-analysis","volume":"94","author":"Andrassy","year":"2012","journal-title":"Transplantation."},{"issue":"4","key":"10.1016\/j.trim.2023.101857_bb0130","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/ajt.15688","article-title":"Belatacept-based immunosuppression with simultaneous calcineurin inhibitor avoidance and early corticosteroid withdrawal: a prospective, randomized multicenter trial","volume":"20","author":"Woodle","year":"2020","journal-title":"Am. J. Transplant."},{"issue":"4","key":"10.1016\/j.trim.2023.101857_bb0135","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/14740338.2019.1599858","article-title":"An update on the safety of tacrolimus in kidney transplant recipients, with a focus on tacrolimus minimization","volume":"18","author":"Jouve","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"issue":"1","key":"10.1016\/j.trim.2023.101857_bb0140","first-page":"1","article-title":"Variations in practice to therapeutic monitoring of tacrolimus following primary adult liver transplantation","volume":"7","author":"Dasari","year":"2016","journal-title":"Int. J. Organ. Transplant. Med."},{"issue":"26","key":"10.1016\/j.trim.2023.101857_bb0145","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1056\/NEJMra033540","article-title":"Immunosuppressive drugs for kidney transplantation","volume":"351","author":"Halloran","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.trim.2023.101857_bb0150","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/infdis\/jiz114","article-title":"Impact of pretransplant donor BK Viruria in kidney transplant recipients","volume":"220","author":"Tan","year":"2019","journal-title":"J. Infect. Dis."},{"issue":"12","key":"10.1016\/j.trim.2023.101857_bb0155","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1080\/1744666X.2020.1693263","article-title":"Impact of low tacrolimus exposure and high tacrolimus intra-patient variability on the development of de novo anti-HLA donor-specific antibodies in kidney transplant recipients","volume":"15","author":"Mendoza Rojas","year":"2019","journal-title":"Expert. Rev. Clin. Immunol."}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327423000746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327423000746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T18:03:07Z","timestamp":1760810587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327423000746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":31,"alternative-id":["S0966327423000746"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2023.101857","relation":{},"ISSN":["0966-3274"],"issn-type":[{"value":"0966-3274","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increased CMV disease and \u201csevere\u201d BK viremia with belatacept vs. sirolimus three-drug maintenance immunosuppression","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2023.101857","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101857"}}